Novocure Reports Third Quarter 2015 Operating and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
JMP Securities Starts NovoCure Ltd. (NVCR) at Market Outperform
October 27, 2015 8:18 AM EDTJMP Securities initiated coverage on NovoCure Ltd. (NASDAQ: NVCR) with a Market Outperform rating and a price target of $43.00.
For an analyst ratings summary and ratings history on NovoCure Ltd. click here. For more ratings news on NovoCure Ltd. click here.
Shares of NovoCure Ltd. closed at $20.58 yesterday.
... MoreWedbush Starts NovoCure Ltd. (NVCR) at Outperform
October 27, 2015 7:28 AM EDTWedbush initiates coverage on NovoCure Ltd. (NASDAQ: NVCR) with a Outperform rating and a price target of $30.00.
Analyst Tao Levy commented, " NovoCure is a rapidly emerging, commercial stage company whose flagship Tumor Treating Fields (TTFields) technology reverses tumor growth by disrupting cell... More
Novocure (NVCR) Reports Q3 Loss of $2.09/Share
October 26, 2015 4:14 PM EDTNovocure (NASDAQ: NVCR) reported Q3 EPS of ($2.09), versus ($1.45) reported last year. Revenue for the quarter came in at $8.95 million, versus $4.37 million reported last year.
Third Quarter 2015 Operating Statistics
354 prescriptions were received in the quarter, an... More